Home
Search:
1146 feeds
357 categories
0 articles (<24 hours)
34 registered users

Use the Mobile version
Mobile

Follow our Twitter feed

View our Linkpartners
Links

Username:
Password:

Register | Retrieve

General


RSS FeedsFDA accepts Roche´s supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer
(WorldNews Switzerland)

 
 

17 january 2019 09:31:39

 
FDA accepts Roche´s supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer
(WorldNews Switzerland)
 


Basel, 17 January 2019 FDA accepts Roche`s supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company`s supplemental Biologics License Application (sBLA) for Tecentriq® (atezolizumab) in combination with Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) and carboplatin for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR or ALK genomic tumour aberrations. The FDA is...


 
21 viewsCategory: General > Europe > Switzerland
 
Lonza Announces Initiation of S&P Credit Rating with Investment Grade of BBB+ and Stable Outlook
(WorldNews Switzerland)
WISeKey Completes Sale of QuoVadis SSL/TLS, PKI Businesses to DigiCert for $45 Million
(WorldNews Switzerland)
 
 
blog comments powered by Disqus


Copyright © 2008 - 2024 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice.
Other websites of Indigonet Services B.V.: Nieuws Vacatures Science Tweets Nachrichten